Hayley Burgess SVP, Inovalon, touches on Specialty pharmacies grappling with surging drug complexity and costs while ...
Michael O' Rurke , CEO Re-Vana Therapeutics, discusses positioning Re-Vana as a long-term platform partner by leveraging its ...
PE: How can teams reduce patient burden without weakening their science? Schwab: Number one is lean trial design. We should ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback